Induction of Nevi and Skin Tumors in *Ink4a/Arf Xpa* Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures

Arne van Schanke^{1,2}, Gemma M.C.A.L. van Venrooij², Marjan J. Jongsma², H. Alexander Banus⁴, Leon H.F. Mullenders³, Henk J. van Kranen⁵ and Frank R. de Gruijl²

¹ Dermatology Department, University Medical Centre Utrecht, Utrecht, the Netherlands; Departments of ² Dermatology and ³ Toxicogenetics, Leiden University Medical Centre, Leiden, the Netherlands; ⁴ Laboratory of Vaccine-Preventable Diseases; and ⁵ Toxicology, Pathology, and Genetics Department, National Institute of Public Health and the Environment, Bilthoven, the Netherlands

Requests for reprints: Frank de Gruijl, Dermatology Department, Leiden University Medical Centre, PO Box 9600, 2300RC Leiden, the Netherlands. Phone: 31-71-5262497; E-mail: f.r.de_gruijl@lumc.nl

Abstract

Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16^{*Ink4a*} expression is often lost in malignant progression. To ascertain the effect of these risk factors, pigmented hairless *Ink4a/Arf*^{-/-}, *Xpa*^{-/-} knockout mice were subjected to various combinations of neonatal [7,12-dimethylbenz(a)anthracene (DMBA) or UVB exposure] and adult treatments (12-*O*-tetradecanoylphorbol-13-acetate or subacute daily UVB exposure or intermittent overexposure). Nevi occurred earliest, grew largest, and were most numerous in mice exposed to DMBA followed by intermittent UVB overexposure [effect of six minimal edematous doses (MED), 1x/2 weeks > 4 MED 1x/wk]. Neonatal UV exposure enhanced nevus induction but lost its effect after 200 days. The *Xpa*^{-/-} mice proved exquisitely sensitive to UV-driven nevus induction, indicating the involvement of pyrimidine dimer DNA lesions, but *Xpa*^{+/+} mice developed many more nevi (>40 per mouse) at high UV dosages not tolerated by *Xpa*^{-/-} mice. *Ink4a/Arf*^{-/-} mice developed most skin tumors faster, but surprisingly developed nevi slower than their heterozygous counterparts especially after neonatal UV exposure. Despite raising >1,600 nevi, only six melanomas arose in our experiments with *Ink4a/Arf* knockout mice (five of which in *Xpa*^{+/+} mice at high UV dosages). In contrast to human nevi, these nevi lacked hotspot mutations in *Braf* or *Ras* genes, possibly explaining the lack of malignant progression in the *Ink4a/Arf*^{-/-} mice. Hence, although our experiments did not effectively emulate human melanoma, they provided clear evidence that intermittent UV overexposure strongly stimulates and the *Ink4a/Arf*^{-/-} genotype may actually impair nevus development. (Cancer Res 2006; 66(5): 2608-15)

Introduction

The most important environmental risk factor for skin cancers, including cutaneous malignant melanomas, is exposure to solar UV radiation. Epidemiologic studies indicate that unlike squamous cell carcinomas (SCC), cutaneous malignant melanomas are not associated with chronic exposure, but with sunburns, especially those in childhood (1). Another important risk factor for cutaneous malignant melanoma is inheritance of mutations in so-called melanoma genes, which predispose individuals to the development of melanoma. Thus far, familial clusters have led to the identification of two melanoma genes: *CDKN2A* and *CDK4* (2). The *CDKN2A* gene encodes two proteins—p16^{Ink4a} and p14^{Arf}. p16^{Ink4a} regulates cell cycle progression by inhibiting cyclin-dependent kinases, such as CDK4. Two exons in *CDKN2A* can form an alternative reading frame for the p14^{Arf} protein (p19^{Arf} in mice; ref. 3), which enhances p53 function by blocking MDM2 (4). Mutations in the *CDKN2A* tumor suppressor gene impair the function of p16^{Ink4a} and/or p14^{Arf}, thus facilitating "unauthorized" proliferation of cells with, for example, erroneous activation of the Ras pathway. This is illustrated by a highly increased *N-Ras* mutation frequency in melanomas of patients with germ line *CDKN2A* mutations (5). Uncontrolled proliferation may cause further mutation fixation in cells with (UV-) damaged DNA. Consequently, mice lacking both *Ink4a* and *Arf* have an enhanced sensitivity to tumorigenesis (6). Mice nullizygous for either p16^{Ink4a} or p19^{Arf} crossbred with Ras transgenes rapidly develop melanomas that lack expression of p19^{Arf} or p16^{Ink4a}, respectively, indicating that both products of the *CDKN2A* locus participate in melanoma suppression (7). Similarly, although *CDKN2A* is only completely lost or mutated in a minority of cutaneous malignant melanoma, most cutaneous malignant melanomas and their metastases lack p16^{Ink4a} expression (8). The expression is usually high in nevi (9), which commonly bear activating mutations in the oncogenes *Braf* or *N-Ras* (9). Loss of p16^{Ink4a} cell cycle control thus seems to give way to the mitogenic signaling from *Ras* or *Braf* and contributes to progression of nevus to cutaneous malignant melanoma (10).

Sunlight causes various types of DNA damage, such as pyrimidine dimers, of which the importance in skin tumorigenesis is exemplified by characteristic signature mutations found in oncogenes and tumor suppressor genes in nonmelanoma skin cancer (11, 12).

Pyrimidine dimers can be repaired accurately by nucleotide excision repair. People with the rare genetic disorder xeroderma pigmentosum lack nucleotide excision repair and are up to 1,000 times more prone to skin cancers, including melanoma, compared with the general population (13). This condition can result from mutations in components of the nucleotide excision repair system, such as *Xpa*.

In wild-type mice, treatment with only UV radiation does not induce melanomas, but UV can accelerate their formation in combined treatments with chemical carcinogens (14–16). Similarly, UV radiation can strongly enhance melanoma formation in transgenic mouse strains that spontaneously develop these tumors (17).

Mice with a targeted deletion of the *Ink4a/Arf* locus do not develop melanomas spontaneously nor when exposed to UV radiation or chemical carcinogens (6). However, crossbreeding these mice with *H-Ras*^{G12V} transgenic mice (carrying an activated *Ras* oncogene under a tyrosine promoter) raised the percentage of animals with melanomas from 2% in *Ink4a/Arf* wild types to 60% in *Ink4a/Arf* knockouts, illustrating the importance of *CDKN2A* in preventing melanoma (18).

H-Ras mutations in keratinocytes can be effectively induced in *Xpa* knockout mice by chronic UV irradiation, leading to the formation of papillomas; however, no melanomas were observed in these experiments (19). We hypothesized that if *H-Ras* (or *N-Ras*) mutations could also be induced in melanocytes by UVB irradiation of *Xpa* knockout mice, and in crossbreds with *Ink4a* knockout mice, these *Ras* mutations could lead to the development of melanomas. Moreover, loss of p16^{*Ink4a*} was found to be related to malignant progression of (UV-induced) skin carcinomas (20). The specific UV regimen (chronic versus intermittent exposure) can be expected to be decisive for the efficacy of different types of skin cancers. Therefore, we ascertained the skin tumorigenic effect of various UV exposure regimens on pigmented hairless *Ink4a/Arf* knockout and *Ink4a/Arf Xpa* double-knockout mice, specifically looking at nevi induction (risk factor of melanomas and putative precursors) and progression to melanoma.

Materials and Methods

Mice. *Ink4a/Arf* knockout (courtesy of Drs. R. DePinho and L. Chin; ref. 6) and *Xpa* knockout mice (courtesy of Dr. Van Steeg; ref. 21) were crossbred (F₃) in a pigmented hairless background (Hr, Charles River, Wilmington, MA). Cohorts of neonates from three to five nests of *Ink4a/Arf*^{-/-} x *Ink4a/Arf*^{+/-} parents entered the experiments, thus reproducing these genotypes in approximately equal numbers; in experiment 1, all mice were *Xpa*^{-/-}; in experiment 2, all mice were *Xpa*^{+/-}.

Mice were kept as described (22) and permission was obtained from the Ethical Commission on Animal Experiments of the University Medical Center Utrecht, Utrecht, the Netherlands.

Chemical exposures. 7,12-Dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma (Zwijndrecht, the Netherlands). Mice of the relevant cohorts were topically treated once at 3 days of age with 50 µL DMBA solution (0.2 or 2 mg/mL in acetone for *Xpa*^{-/-} and *Xpa*^{+/-}, respectively). Mice in the TPA-treated cohort were topically exposed twice a week to 50 µL TPA solution (0.5 mg/mL in acetone) commencing at 4 weeks of age until sacrifice.

UVB exposure. For UVB exposure, cages were placed in an automatically time-switched irradiation setup (23) equipped with Philips TL12/40W lamps (Philips, Eindhoven, the Netherlands). The doses were expressed as multiples of the minimal edema dose (MED, determined earlier; ref. 24). For TL12/40W lamps, 1 MED equals 500 J/m² UV in *Xpa*^{+/-} mice and 62.5 J/m² in *Xpa*^{-/-} mice. Six MED was the highest tested dose that caused a clear sunburn without blistering or further complications that acutely compromised the condition of the animals (i.e., highest tolerated dose). For neonatal exposures, pups were exposed separately (to prevent shielding) under maximal lamp intensity for ~15 minutes, immediately after which pups and mothers were rejoined.

Experiment 1. This experiment aimed at optimizing a UVB irradiation scheme to induce melanocytic hyperplasia to form nevi based on a two-stage initiation/promotion protocol (16). First, five promotion treatments of adult mice were compared after neonatal application of DMBA. Subsequently, initiation with DMBA was compared with UV irradiation (4 MED at days 3, 4, and 5 of age) or sham treatment.

The regimens in the adulthood were as follows: I, daily exposure to a suberythral dose of UVB (4/7 MED); II, an equal dose in a single weekly

exposure (4 MED); III, exposure to the highest tolerated UVB dose (6 MED) once every fortnight; IV, TPA twice a week (positive control); V, sham. Neonatal treatments were compared using adult treatments I, III, and V. Two cohorts included *Ink4a/Arf* wild types (Table 1).

Table 1. Overview of tumor outcomes for all treatments in this study

A. Treatments, survival, and melanocytic tumors											
Neonatal treatment, d3 (4, 5) [†]	Adult treatment, d28-end	<i>Ink4a</i> $\frac{n^{--}/n^{++}}{n^{++}/n^{++}}$	Survival (d)	Melanomas		Nevi					
				$\sum n$	$\sum n$	t_m [‡]	Yield				
Experiment 1A [¶]											
1: 10 μ g DMBA	None	12/12/0	226	0	59	108*	0.83*				
2: 10 μ g DMBA	25 μ g TPA 2x/wk	13/13/0	216	0	133	82 ^{ns}	2.08 ^{ns}				
3: 10 μ g DMBA	35.7 J/m ² UV/d	12/11/0	138	0	47	84 ^{ns}	0.85*				
4: 10 μ g DMBA	250 J/m ² UV/wk	7/8/0	120	0	62	66 [¶]	3.00 [¶]				
5: 10 μ g DMBA	375 J/m ² UV/2wk	11/6/0	139	0	132	52 ^{***}	4.71 ^{ns}				
6: 10 μ g DMBA	375 J/m ² UV/2wk	0/8/16	160	1	142	62 ^{ns}	3.74 ^{ns}				
Experiment 1B ^{††}											
7: None UV	None	13/15/0	284	0	16	432 ^{***}	0.00 ^{**}				
8: 250 J/m ² UV	None	8/7/0	256	0	13	300 ^{***}	0.13 ^{**}				
9: None J/m ² UV	375 J/m ² UV/2wk	13/6/0	190	0	48	146 ^{ns}	0.21 ^{ns}				
10: 250 J/m ² UV	375 J/m ² UV/2wk	10/8/0	171	0	48	88 ^{**}	0.83 ^{††}				
11: 250 J/m ² UV	35.7 J/m ² UV/d	7/11/6 ^{‡‡}	143	0	23	152 ^{‡‡}	0.61 [*]				
Experiment 2 ^{‡‡}											
12: 100 μ g DMBA	3,000 J/m ² UV/2wk	7/12/0	140	1	808	51 ^{***}	32.6 ^{**}				
13: 2,000 J/m ² UV	3,000 J/m ² UV/2wk	14/13/0	235	1	53	205 ^{ns}	0.26 ^{ns}				
14: None DMBA	3,000 J/m ² UV/2wk	9/11/0	254	3	53	195 ^{‡‡}	0 ^{‡‡}				
15: 10 μ g DMBA	375 J/m ² UV/2wk	4/6/7	229	0	18	133 ^{ns}	0 ^{ns}				
B. Outcomes of nonmelanocytic tumors											
Treatment	Papillomas			Cysts			SCCs		Sarcomas GL OT		
	$\sum n$	t_m	Yield	$\sum n$	t_m	Yield	$\sum n$	t_m	$\sum n$	t_m	$\sum n$
1	74	133 ^{**}	0.67 ^{ns}	19	175 ^{ns}	0.33 ^{ns}	3	448 ^{**}	1	— ^{*,¶¶}	12 12
2	212	82 ^{ns}	2.50 ^{ns}	10	— ^{ns}	0.27 ^{ns}	4	— ^{**}	3	— ^{**}	5 6
3	287	98 ^{ns}	0.82 ^{ns}	9	172 ^{ns}	0.13 ^{ns}	13	158 ^{ns}	4	— [*]	7 11
4	64	66 [¶]	2.08 [¶]	2	— [¶]	0 [¶]	5	186 [¶]	5	175 [¶]	2 6
5	109	80 ^{ns}	1.00 ^{ns}	6	238 ^{ns}	0.12 ^{ns}	8	— ^{ns}	5	224 ^{ns}	3 10
6	245	90 ^{ns}	1.42 ^{ns}	2	— ^{ns}	0.05 ^{ns}	6	253 ^{ns}	0	— ^{ns}	5 4
7	5	— ^{***}	0.00 ^{**}	17	408 ^{ns}	0.04 ^{ns}	1	— [*]	1	— ^{**}	13 9
8	14	287 ^{***}	0.33 ^{ns}	40	115 ^{ns}	1.67 [*]	1	— [*]	1	— [*]	9 3
9	94	111 ^{ns}	1.58 ^{ns}	24	133 ^{ns}	0.63 ^{ns}	5	275 ^{ns}	0	— [*]	8 5
10	93	102 ^{††}	1.50 ^{††}	9	— ^{††}	0.44 ^{††}	3	285 [†]	6	336 ^{††}	10 10
11	183	96 [*]	3.00 ^{**}	42	103 ^{**}	1.17 ^{ns}	16	— [*]	1	—	4 1
12	707	51 ^{***}	31.1 ^{***}	26	167 ^{ns}	0.63 ^{ns}	5	385 ^{ns}	19	153 ^{***}	6 10
13	27	275 ^{ns}	0 ^{ns}	114	83 ^{***}	2.04 ^{***}	0	— ^{ns}	20	282 ^{**}	3 6
14	102	231 ^{‡‡}	0.05 ^{‡‡}	25	175 ^{‡‡}	0 ^{‡‡}	9	— ^{‡‡}	5	— ^{‡‡}	8 7
15	55	119 ^{**}	1.20 ^{ns}	5	— [*]	0.20 ^{ns}	1	— ^{ns}	9	325 [*]	1 0

NOTE: Levels of significance for yields were obtained by ANOVA and for tumor-free survival by Cox regression (corrected for genotype effects).

Abbreviations: GL, generalized lymphoma; OT, other tumors such as hemangiomas, papillomas of the conjunctiva, lung, brain, and colorectal tumors; Σn , total number of tumors observed per group; ns, not significant.

* DMBA treatment at day 3; UVB treatment at days 3, 4, and 5.

[†]Numbers of *Ink4a/Arf* knockouts, heterozygotes, and wild types per group. All animals in experiment 1 were *Xpa*^{-/-}; all animals in experiment 2 were *Xpa*^{+/+}.

[‡] t_m values were obtained from Kaplan-Meier plots.

[§]Yields were compared at 98 days (experiment 1A) or 140 days (experiments 1B and 2).

^{||} For statistics, the group exposed weekly to 250 J/m² UV was used as reference group.

[¶] Level of significance of <0.05.

** Level of significance of <0.001.

^{††}For statistics, the group exposed neonatally to 250 J/m² and in adulthood to 375 J/m² UV per fortnight was used as reference group.

^{†††}Level of significance of <0.01.

^{§§}For uniformity, statistical comparisons are based on homozygous knockouts and heterozygotes only.

^{||||} For statistics, the group sham exposed neonatally and to 3,000 J/m² UV per fortnight in adulthood was used as reference group.

^{¶¶} Numbers refer to Table 1A.

*** Could not be calculated (percentage of affected animals never reached 50).

Experiment 2. *Ink4a/Arf*^{-/-} mice (*Xpa*^{+/+}) were neonatally exposed to DMBA, UV, or sham treated, followed by adult promotion treatment III. Doses were adapted (see above) to *Xpa* wild-type mice, which are less sensitive than *Xpa*^{-/-} mice to the acute effects of UVB radiation and DMBA. To allow a complete comparison, we included a cohort of *Ink4a/Arf* knockout mice (*Xpa*^{+/+}) receiving exactly the same low doses (expressed in J/m² UV or μ g DMBA) as the *Ink4a/Arf* knockouts in an *Xpa*^{-/-} background. The treatments for both experiments are summarized in Table 1.

Characterization of tumors. Mice were checked weekly to record tumors and other abnormalities (23), and kept until tumors >10 mm across developed, illness occurred, or until 16 months of age. After sacrifice, the organs were thoroughly screened for abnormalities and samples of nevi and (skin) tumors were collected in formalin. Paraffin-embedded 5 μ m tissue sections were H&E stained and

evaluated by experienced pathologists. To establish the diagnosis, immunohistochemical stainings were done with the following antibodies: polyclonal goat anti-mouse Trp-1 (1:100, Santa Cruz Biotechnology, Heidelberg, Germany), polyclonal goat anti-human Trp-2 (1:100, Santa Cruz Biotechnology), monoclonal mouse anti-human Melan-A/Mart-1 (1:500, clone A103, DAKO, Glostrup, Denmark), polyclonal rabbit anti-cow S100 (1:8,000, DAKO), monoclonal mouse anti- β -smooth muscle actin (1:10,000, clone 1A4, Sigma), and monoclonal mouse anticytokeratin (1:100, clone AE1/AE3, Chemicon, Temecula, CA).

Proliferative signaling in nevi was established by staining with polyclonal rabbit anti-human Ki-67 (1:1,000, Novocastra, Newcastle upon Tyne, United Kingdom), polyclonal rabbit anti-human pERK1/2 (1:200, Cell Signaling, Beverly, MA), and rabbit polyclonal anti-p53 (1:500, CM-5, Novocastra). Sections from murine SCCs and colon cancers served as positive controls for proliferation markers.

Microdissection and mutation analyses. From mice of each treatment group, nevi over 2 mm in diameter ($n = 46$) and all melanomas ($n = 6$) were analyzed for mutations. Five-micrometer sections of nevi and melanomas were fixed on PEN foil-coated glass slides (Leica Microsystems, Wetzlar, Germany) and deparafinized. Specimens (unstained) of at least 50 cells were microdissected using an AS LMD laser microdissection microscope (Leica Microsystems) and collected in 8 mL FLB buffer with Proteinase-K (NucleoSpin DNA Trace kit, Machery Nagel, Düren, Germany). DNA was isolated using NucleoSpin columns according to the instructions of the manufacturer.

Fragments of *Braf* exon 15, *N-Ras* exons 1 and 2, *H-Ras* exons 1 and 2, and *K-Ras* exons 1 and 2 were PCR amplified in single fashion (primers and fragment sizes; Table 2). PCR reactions contained 25 μ L Hotstar Taq Master Mix (Qiagen, Venlo, the Netherlands), 60 pmol of each primer, and 5 μ L DNA (~ 5 ng) per reaction (total volume 25 μ L). PCR products were reamplified in a 25 μ L reaction. Depending on sequencing direction (Table 2), the 3' or 5' end of the PCR product was biotinylated using biotinylated primers.

Table 2. PCR and pyrosequencing primers and mutations observed in nevi ($n = 46$) and melanomas ($n = 6$)

Gene	PCR primers: universal biotinylated, gene-specific forward and reverse	Amplicon size	Pyrosequencing primer (sequencing direction)	Informative sequences (%)	Mutations found
<i>Braf</i> exon 15	Uni-biotin-rev*, 5'-TTCCTTTACTTACTGCACCTCAGA-3'; 5'-AGCGCTGCTCCGGTTCATAGATTCATCCACAAAATAGATCCAGA-3'	127	GTGACTTTGGTCTAGCCAC (forward)	60	None
<i>N-Ras</i> exon 1	Uni-biotin-rev, 5'-ACAGGTTTTGCTGGTGTGA-3'; 5'-AGCGCTGCTCCGGTTCATAGATTCATCCACAAAGTGTTCTGG-3'	112	AAACTGGTGGTGGTTGGAGC (forward)	82	None
<i>N-Ras</i> exon 2	Uni-biotin-for†, 5'-GGGACACCGCTGATCGTTTATCCAGGATTCTTACCGAAA-3'; 5'-CCTTCGCCTGTCCTCATGTA-3'	125	AGGAGTACAGTGCCATGAGA (reverse)	70	C>T, codon 60 (1 nevus)
<i>H-Ras</i> exon 1	Uni-biotin-rev, 5'-CTGGCTAAGTGTGCTTCT-3'; 5'-AGCGCTGCTCCGGTTCATAGATTGGTGAGCTCTGCCTACCTGC-3'	199	AGCTTGTGGTGGTG (forward)	41	None
<i>H-Ras</i> exon 2	(No universal biotinylated primer) 5'-CGTGTGTTTTGCAGGACTC-3'; 5'-biotin-labeled-ATGTAAGTGGTCCCGCATGG-3'	122	GGACATCTTAGACACAGCAG (forward)	73	None
<i>K-Ras</i> exon 1	Uni-biotin-rev, 5'-AGGCCTGCTGAAAATGACTG-3'; 5'-AGCGCTGCTCCGGTTCATAGATTCTAGGGTCATACTCATCCAC-3'	118	AAACTTGTGGTGGTTGGAGC (forward)	89	G>A, codon 13 (1 nevus)
<i>K-Ras</i> exon 2	Uni-biotin-rev, 5'-TTGGATATTCTCGACACAGCA-3'; 5'-AGCGCTGCTCCGGTTCATAGATTTAAACCCACCTATAATGGTGAA-3'	144	GATATTCTCGACACAGCAGG (forward)	87	None

* 5'-Biotin-GGGACACCGCTGATCGTTTA-3' (universal biotinylated forward primer).

† 5'-Biotin-GCTGCTCCGGTTCATAGATT-3' (universal biotinylated reverse primer).

Biotinylated PCR products were immobilized on streptavidin Sepharose HP beads (B&L Systems, Maarssen, the Netherlands) in binding buffer [10 mmol/L Tris-HCl, 2 mol/L NaCl, 1 mmol/L EDTA, and 0.1% Tween 20 (pH 7.6)]. The beads were transferred to a 0.2 mol/L NaOH solution to separate the strands. The beads containing the biotinylated strand were washed in 10 mmol/L Tris-acetate (pH 7.6) and fed into a 96-well plate containing the pyrosequencing primer (0.15 μ L, 100 pmol/ μ L) and annealing buffer [44.85 μ L, 20 mmol/L Tris-acetate, and 2 mmol/L MgAc₂ (pH 7.6)].

The plate was transferred into a PSQ96MA (Pyrosequencing, Biotage, Uppsala, Sweden) where real-time sequencing was done of the sequences surrounding codon 599 of *Braf*; codons 12 and 13 of *N*-, *H*-, and *K-Ras* exon 1; and codon 61 of *N*-, *H*-, and *K-Ras* exon 2, respectively, with the PSQ96 SNP Reagent kit (B&L Systems). Pyrograms were analyzed for deviations from the wild-type sequence.

Along with each lot of PCR reactions, negative controls without DNA and controls without PSQ primer were run, as well as wild-type samples for each gene and exon. Positive controls involved DNA extracted from three papillomas in which *H-Ras* codon 12 mutations were established earlier by allele-specific oligohybridization (19). The same mutations (C>T in transcribed strand) showed up in our pyrosequencing assays.

Analyses and statistics. Kaplan-Meier plots were used for initial exploration of treatment and genotype effects. These effects were confirmed using the Cox proportional hazards model in SPSS 10 software package (SPSS, Chicago, IL). Effects of treatments on tumor yield were evaluated at the median survival of the shortest-lived group by ANOVA with *post hoc* tests by Bonferroni's *t* test for multiple comparisons.

Results

Tumors. Depending on treatment, a variety of tumors and skin lesions developed as outlined in Table 1. When appropriate, genotype effects are given below in the text. Only six melanomas were observed, showing a low grade of differentiation and pigmentation with spindle-shaped cells, and a (diffuse) positivity for S100 or Melan-A/Mart-1. One melanoma occurred in an *Ink4a/Arf*^{+/+} *Xpa*^{-/-} mouse (experiment 1) and five melanomas in *Ink4a/Arf*^{+/-} *Xpa*^{+/-} mice (experiment 2), with no obvious bias in genotype or treatment.

Nevi. Melanocytic nevi appeared as accumulations of melanocytes and pigment-loaded macrophages in the dermis. The vast majority of nevi showed no indications of malignancy, either on macroscopic or microscopic histologic inspection (7%, *n* = 114 evaluated).

Over the entire first experiment, nevi appeared significantly later in *Ink4a/Arf*^{-/-} *Xpa*^{-/-} compared with *Ink4a/Arf*^{+/-} *Xpa*^{-/-} mice (median latency time, *t*_m, of 131 versus 82 days, respectively, *P* = 0.004; Fig. 1A); this difference was most pronounced with neonatal UV exposure followed by 6 MED every fortnight (*t*_m: 140 days versus 74, *P* = 0.0022; Fig. 1B). Moreover, the overall numbers of nevi per animal (yields) were higher in *Ink4a/Arf*^{+/-} compared with *Ink4a/Arf*^{-/-}: 2.5 versus 0.8 nevi per animal at day 140. Notably, this was the only skin lesion in our study of which the induction was slowed down in the *Ink4a/Arf* null mice.

Figure 1. Effect of *Ink4a/Arf* genotype on carcinogen-induced tumorigenesis. *A*, nevus-free survival summed for all groups in experiment 1. *B*, nevus-free survival in *Xpa*^{-/-} (*Ink4a/Arf*^{+/+} and *Ink4a/Arf*^{-/-}) mice neonatally exposed to 4 MED UV on days 3, 4, and 5, and subsequently to 4 MED/2 weeks. *C*, papilloma-free survival summed for all groups in experiment 1. *D*, SCC-free survival in mice neonatally exposed to DMBA and after 4 weeks to various UV regimes. The *P* values represent log-rank test statistics. Note that all tumors except nevi were enhanced by *Ink4a/Arf* deficiency.

Figure 2. Effect of carcinogen treatments on tumor-free survival. *A*, optimization of the adult treatment regimen for nevi. *B*, comparison of neonatal treatments on nevogenic potential. The *P* values in (*A* and *B*) represent log-rank test statistics. *C*, comparison of nevus yields between *Ink4a/Arf* *Xpa* and *Ink4a/Arf* mice exposed to the highest tolerated carcinogenic dose for *Ink4a/Arf* *Xpa* or *Ink4a/Arf* mice. *D*, same comparison for papillomas. *C* and *D*, points, mean; bars, SE.

Neonatal treatment with DMBA, especially in combination with adult erythematous UVB overexposures, remarkably shortened t_m and enhanced yields. Daily suberythematous exposure (4/7 MED) had no discernable effect on nevus development (Fig. 2*A*). Surprisingly, TPA had no significant effect on nevus-free survival, although it raised nevus yields >2-fold compared with controls that received only DMBA.

As 6 MED UVB per fortnight was the most effective stimulus of nevus development, this regimen was used to compare the effects of the neonatal treatments with DMBA, UVB, or no exposure. Although more slowly than DMBA, neonatal UVB also induced nevi as shown in Fig. 2*B*. Correspondingly, nevus yields dropped when DMBA was replaced by UVB.

Experiment 2 used *Xpa* wild-type mice that could be exposed to 10 times higher DMBA concentrations and 8 times higher UVB levels, as their acute sensitivity to these challenges was much lower than that of *Xpa*^{-/-} mice.

Although the t_m for nevi was almost identical for the groups exposed to DMBA and 6 MED UVB per fortnight, the yields eventually rose 5.5-fold higher in *Xpa*^{+/+} than in *Xpa*^{-/-} mice when both were exposed to their respective highest tolerated doses. When *Xpa* wild types were exposed to the same physical doses as the *Xpa*^{-/-} mice, nevi appeared 2.5 times later than in *Xpa*^{-/-} mice, and eventually reached 5.1-fold lower numbers (Fig. 2*C*).

Papillomas. Papillomas were morphologically presented as hyperplastic keratinocytes protruding from the epidermal surface and positive for pan-cytokeratin.

Over the entire first experiment, papillomas were slightly augmented in *Ink4a/Arf*^{-/-} compared with *Ink4a/Arf*^{+/+} mice (t_m of 95 versus 108 days, respectively, *P* =

0.03; Fig. 1C). Correspondingly, the numbers of papillomas per animal were higher in *Ink4a/Arf*^{-/-} *Xpa*^{-/-} mice compared with *Ink4a/Arf*^{+/-} *Xpa*^{-/-} mice.

All neonatal and adult treatments used in these studies raised papilloma yields and prevalences but the differences between adult treatment regimens were small and statistically insignificant. Generally, earlier onset of papillomas was associated with higher numbers of papillomas per animal (Table 1). The papilloma yields for *Xpa* wild-type mice (experiment 2) were remarkably higher than for *Xpa*^{-/-} mice (experiment 1) when both were exposed at their respective highest tolerated doses. However, when the same physical doses were used, yields were slightly higher in *Xpa*^{-/-} mice (Fig. 2D).

Squamous cell carcinomas. SCCs were characterized by infiltratively growing keratinocytes, keratinization, and a positive immunohistochemical staining with pan-cytokeratin.

On average, SCCs occurred ~3-fold earlier in *Ink4a/Arf*^{-/-} *Xpa*^{-/-} mice than in *Ink4a/Arf*^{+/-} *Xpa*^{-/-} mice, but this difference was not evident in the separate treatments due to the small numbers of tumors. The overall effect of genotype on UV-induced SCC formation is illustrated in Fig. 1D. SCCs appeared earlier and in higher numbers with 4/7 MED/d than with 4 MED weekly.

Sarcomas. S.c. pleiomorphic spindle cell tumors, morphologically presenting with a low grade of differentiation, often highly infiltrated with lymphocytes, densely vascularized, and negative for the immunohistochemical markers S100, Melan-A/Mart-1, Trp-1, Trp-2, and pan-cytokeratin were categorized as (unspecified) sarcomas.

Sarcoma prevalence was affected by *Ink4a/Arf* genotype and treatments. Although not evident from the small number of tumors in each treatment, averaged over the DMBA-treated groups in experiment 1, sarcoma yield was 3.5-fold higher in the *Ink4a/Arf*^{-/-} mice compared with *Ink4a/Arf*^{+/-} mice ($P = 0.005$). Further, combinations of neonatal DMBA or UV exposure and adult intermittent erythematous UV exposure raised sarcoma yields (Table 1).

Cysts. Epidermal cysts in the dermis morphologically presented as spheres of inward differentiating keratinocytes converging on central keratin deposits and often contained melanin pigment.

The occurrence of cysts was not affected by the *Ink4a/Arf* genotype. Cysts appeared remarkably earlier and with higher yields in *Xpa*^{+/-} mice exposed neonatally to UVB (Table 1).

Other tumors. Generalized lymphoma appeared as large nodules of histologically proven lymphocytes in multiple organs, such as liver and spleen. *Ink4a/Arf*^{-/-} mice were strongly predisposed to develop lymphomas as opposed to *Ink4a/Arf*^{+/-} mice. None of the treatments had an effect on lymphoma-free survival.

Other tumors were rare and included s.c. hemangiomas, showing widely dilated and aberrantly growing vascular channels and internal tumors at various locations.

Genetic analyses of nevi and melanomas. PCR-amplified DNA extracted from microdissected nevi ($n = 46$) and melanomas ($n = 6$) gave informative sequences in 74% of the 287 samples tested. The vast majority of these samples contained

no hotspot mutations in *H*-, *N*-, and *K*-*Ras* codons 12, 13, or 61 as found in UV and DMBA-induced tumors, or the *Braf* codon 599 mutation as found in human nevi. Two nevi, however, contained mutations in *K*-*Ras* exon 1 and *N*-*Ras* exon 2 (Table 2).

Proliferation marker responses in nevi and melanomas. Sections from 33 nevi were stained for phospho-ERK1/2, Ki-67, and p53 (melanin was bleached and murine skin carcinomas served as positive controls). All but one were found to be negative for pERK1/2, and all were negative for p53. The majority of nevi was negative for Ki-67. Only two nevi (6%) showed scattered Ki-67-positive cells; one contained a small nest of pERK1/2-positive cells that coincided with Ki-67 positivity. The two Ki-67 positive nevi originated from an *Ink4a/Arf*^{-/-} *Xpa*^{+/+} and an *Ink4a/Arf*^{+/-} *Xpa*^{-/-} mouse that both received neonatal sham treatment and biweekly 6 MED exposures. All six melanomas were negative for pERK1/2 but showed an abundance of Ki-67-positive cells.

Discussion

This study compared several neonatal and adult treatments for their effects on nevus and melanoma development in mice. Although nevi rarely progressed to melanomas, remarkable differences in nevus size, multiplicity, and nevus-free survival were observed between treatments. Intermittent exposures to erythematous UVB doses (4 MED/wk or 6 MED/fortnight) caused a marked increase in nevus size and number and corresponding decrease in nevus-free survival compared with groups receiving low daily exposure (4/7 MED) or controls receiving no treatment in adulthood. An accelerating effect of intermittent erythematous UVB exposures on nevi was also found when neonatal DMBA exposure was replaced by neonatal UVB exposures.

Together, these data confirm the epidemiologic observation in humans that sunburns increase nevus numbers in contrast to chronic low exposures (25). Furthermore, the contrasting effects of intermittent erythematous and daily suberythematous UVB exposures match well with earlier experiments: single erythematous exposures stimulated murine melanocyte proliferation, whereas fractionated exposures were ineffective (26). Similarly, exposure of human nevi to erythemagenic doses of UVB radiation led to an increase in proliferation markers within 4 days after exposure as opposed to repeated suberythemagenic exposures (27). Taken together, these results show that erythemagenic UVB exposures are powerful stimuli of melanocyte proliferation and nevi formation, in contrast to equal total doses fractionated into suberythematous exposures. Given the release of melanocyte-stimulating cytokines and growth factors such as endothelin-1 and stem cell factor by keratinocytes in erythemous skin (28–30), it is conceivable that paracrine stimulation contributes to melanocyte proliferation induction and nevus development.

The chemical promoter TPA had only minor effects on nevus formation in our study and did not enhance melanoma formation in *Tyr-Ras* mice treated with DMBA (31). These results suggest that in doses that are effective on keratinocytic tumors, TPA is only a weak promoter of melanocyte hyperproliferation, in contrast to intermittent UVB overexposure.

Neonatal treatment with DMBA or UVB radiation enhanced, but was no prerequisite for, the formation of nevi (i.e., nevi also arose in untreated control mice and in mice UV exposed only in adulthood). The enhancement of nevus formation by neonatal UVB exposures resembles the epidemiologic finding that neonatal UVB exposures contribute to nevus development (32). The greater

efficacy of DMBA than UV in neonatal exposure may result from several factors. First, DMBA dissolved in acetone may penetrate through hair shafts deeper into the skin than UV radiation and consequently affect directly the many melanocytes residing at the root of the hair shaft. Second, the mutagenic potential of DMBA DNA adducts may be greater than that of UV-induced DNA adducts. Third, melanin may provide better protection against UV radiation than against DMBA.

Besides the treatment effects, deficiencies in either *Xpa* or *Ink4a/Arf* showed prominent effects on nevus formation. When mice were exposed to identical low doses, nevus numbers were 5-fold higher in *Xpa*^{-/-} than in *Xpa*^{+/+} mice, indicating a role of nucleotide excision repair in preventing nevus formation. However, the high acute sensitivity to UV radiation and DMBA prohibited higher exposures of *Xpa*^{-/-} mice. When *Xpa*^{+/+} mice were exposed to their highest tolerated dose, nevus numbers rose 27-fold higher than when these mice were exposed to an 8-fold lower dose, equal to the highest tolerated dose for *Xpa*^{-/-} mice. Thus, the maximum attainable yield of nevi in *Xpa*^{+/+} mice far exceeded that attainable in *Xpa*^{-/-} mice (Fig. 3A versus B).

Figure 3. Comparison of *Xpa* knockout and wild-type mouse exposed to their respective highest tolerated doses. *A*, *Ink4a*^{-/-} *Xpa*^{-/-} mouse neonatally exposed to 0.01 mg DMBA and as an adult to 375 J/m² UV/2 weeks. *B*, *Ink4a*^{-/-} mouse exposed neonatally to 0.1 mg DMBA and to 3 kJ/m² UV/2 weeks, photographed at 15 weeks of age.

Remarkably, the combined p16^{*Ink4a*} p19^{*Arf*} deficiency inhibited nevus development, whereas most other skin tumors were stimulated by this deficiency. This may indicate that the critical cell cycle checkpoints upon UV irradiation are regulated differently in melanocytes than in keratinocytes. Our group found no apparent *in vivo* effects of *Ink4a/Arf*^{-/-} genotype on UV-induced cell cycle arrest and apoptosis in keratinocytes,⁶ but a lack of p16 has been reported to abrogate UV-induced G₂ arrest in melanoma cell lines (33). Such a failure in G₂ arrest may conceivably

compromise the survival of normal melanocytes with DNA damage and thus impair nevus development.

The regimens that most effectively induced nevi in our experiments (i.e., neonatal and intermittent UV exposure) were also related to increased melanoma risk in humans, but melanomas were rare in our experiments. In earlier experiments (16), DMBA treatment and subsequent exposure to UVB radiation produced melanomas in 25% of hairless mice; a substantially higher percentage than in our experiments. This discrepancy may possibly be attributed to differences in mouse strains and exposure regimens.

The experiments with *Xpa*^{+/+} mice yielded more melanomas (in 8% of 64 carcinogenically challenged mice) than experiments with *Xpa*^{-/-} mice (in 0.5% of 205 carcinogenically challenged mice). The lower carcinogenic dosages that had to be used on the *Xpa*^{-/-} mice apparently very much restricted the melanoma yield attainable in these mice. No obvious preference for melanoma development in either *Ink4a/Arf*^{-/-} or *Ink4a/Arf*^{+/-} mice was noted, but the low number of melanomas hampers any firm conclusion beyond the fact that the present experiments were ineffective in raising melanoma. As opposed to the current UV-inducible melanoma models that are based on prior receptor tyrosine kinase pathway activation (34), we attempted to establish a UV-inducible melanoma model based on prior inactivation of the p16^{*Ink4a*} and/or p14^{*Arf*} pathways. Although p16^{*Ink4a*}-specific knock-in models form melanomas upon DMBA exposure (7, 35), their responses to UV exposure remain to be established.

Given the large increase of melanoma incidence in *H-Ras*^{G12V} mice when crossbred with *Ink4a/Arf* knockouts (18), it is questionable whether the present experiments with *Ink4a/Arf* knockout mice were effective in introducing oncogenic changes strong or specific enough to express the higher melanoma risk in these mice. To investigate this point more closely, we analyzed the experimentally induced nevi for hotspot mutations in *Ras* or *Braf* genes, activation of pERK1/2 (downstream of *Ras*), proliferative activity (i.e., cycling cells expressing Ki67), and p53 expression (halting cell cycle progression, e.g., in senescence).

We collected nevus biopsies from mice of various genotypes and different exposure regimens and microdissected pigmented sections to restrict samples to melanocytes. Pyrosequencing of the extracted and PCR-amplified DNA rarely detected activating *Braf*, *N-*, *H-*, and *K-Ras* hotspot mutations commonly found in human melanomas and nevi.

The absence of a strong expression of phosphorylated ERK1/2 indicated that this branch of the *Ras* pathway was not activated in the nevi. Moreover, Ki67 positive cells were generally rare in the nevi, indicating a very low proliferation. p53 expression was not found in nevi, indicating it played no role in stagnation of nevus growth.

Apparently, these nevi arose from a transient burst (or repeated bursts) of proliferation in some melanocytes which subsequently halted as a certain contiguous mass of melanocytes was formed. In contrast to the singular interfollicular melanocytes, the melanocytes in these nevi were deeply pigmented (impermeable to UV light), possibly indicating an advanced stage of differentiation. In contrast, Ki-67 stained positive in all melanomas, supporting the notion that these tumors were indeed malignant and highly proliferative.

Differences in the induction of nonmelanocytic tumors were most strongly determined by the differences in genotypes. The homozygous *Xpa* knockout led to

an increased sensitivity for UV-induced SCCs and papillomas, as described earlier (19). *Ink4a/Arf*^{-/-} mice had an increased susceptibility to spontaneous lymphoma formation and to UVB/DMBA-induced sarcomas, papillomas and SCCs. These results are consistent with earlier reports (6). The enhanced formation of papillomas and SCCs in the absence of a functional *p16^{Ink4a}* gene supports the functional role of *p16^{Ink4a}* mutations in human SCCs (20).

Treatment effects on nonmelanocytic tumors included the neonatal UVB-provoked augmentation of epidermal cysts, which differ morphologically to spontaneous cysts in hairless mice (36). This effect was only significant in experiment 2 with *Xpa* wild-type mice with higher dosages. Carcinomas tended to be more effectively induced by chronic than intermittent UV exposure, but this effect was not firm due to censoring deaths under the latter regimen and consequently low numbers of carcinomas. This is in agreement with earlier observations that fractionation of exposure enhances SCC development (37). Remarkably, the incidence of papillomas was unaffected by dosage fractionation demonstrating that total accumulated exposure determines papilloma risk, regardless of the occurrence of sunburns.

In conclusion, intermittent erythematous UVB exposures were more effective in promoting nevus development than equal weekly dosages spread over daily suberythematous exposures, in contrast to the dose fraction effects on nonmelanocytic tumor types. Furthermore, the prevalence and growth of nevi were impaired in homozygous *Ink4a/Arf* knockouts compared with heterozygotes. Surprisingly, the multiple nevi induced in homozygous *Ink4a/Arf* knockout mice showed very little tendency to progress to malignant melanoma, which may be related to the lack of hotspot mutations in *Braf* and *N-Ras* genes.

Acknowledgments

Grant support: National Dutch Cancer Foundation grant RUL2000-2303 and European Commission grant QLK4-1999-01084.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Heggert Rebel (Dermatology, Leiden University Medical Centre) and Anja Westerman-de Vries (National Institute of Public Health and the Environment) for technical assistance; Enno Dreef (Pathology, Leiden University Medical Centre) and John Zevenhoven (Nederlands Kanker Instituut, Amsterdam, the Netherlands) for immunohistochemical protocols; Ron Wolterbeek (Medical Statistics Department, Leiden University Medical Centre) for advise on statistical analyses; Marjon Pasmooij (Academisch Ziekenhuis Groningen, Groningen, the Netherlands) and Kees Tensen (Dermatology, Leiden University Medical Centre) for advice on analytic assays; Martin van der Valk (Nederlands Kanker Instituut), Wolter Mooi (Vrije Universiteit Medisch Centrum, Amsterdam, the Netherlands), and Johan Toonstra (University Medical Centre Utrecht) for aid in the crucial pathologic evaluations; Dr. H. van Steeg (National Institute of Public Health and the Environment) for the kind gift of *Xpa* knockout mice; and Drs. R. DePinho and L. Chin (Dana-Farber Cancer Institute, Boston, MA) for providing *p16^{Ink4a}/p19^{Arf}* knockout mice.

Footnotes

Note: A. van Schanke is currently at NV Organon, Toxicology and Drug Disposition Department, Schaijk, the Netherlands.

⁶ M. Suttmuller, personal communication.

References

1. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. *Int J Cancer* 1997;73:198–203.
2. Hayward NK. Genetics of melanoma predisposition. *Oncogene* 2003;22:3053–62.
3. Sharpless NE, De Pinho RA. The INK4A/ARF locus and its two gene products. *Curr Opin Genet Dev* 1999;9:22–30.
4. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19^{Arf}, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* 1998;92:713–23.
5. Eskandarpour M, Hashemi J, Kanter L, et al. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. *JNCI Cancer Spectrum* 2003;95:790.
6. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. *Cell* 1996;85:27–37.
7. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L. Both products of the mouse Ink4a/Arf locus suppress melanoma formation *in vivo*. *Oncogene* 2003;22:5055–9.
8. Daniotti M, Oggionni M, Ranzani T, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. *Oncogene* 2004;23:5968–77.
9. Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. *J Invest Dermatol* 1998;110:932–8.
10. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. *Oncogene* 2003;22:3063–9.
11. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. *Proc Natl Acad Sci U S A* 1991;88:10124–8.
12. Daya-Grosjean L, Sarasin A. UV-specific mutations of the human patched gene in basal cell carcinomas from normal individuals and xeroderma pigmentosum patients. *Mutat Res* 2000;450:193–9.
13. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. *Arch Dermatol* 1994;130:1018–21.
14. Epstein JH, Epstein WL, Nakai T. Production of melanomas from DMBA-induced "blue nevi" in hairless mice with ultraviolet light. *J Natl Cancer Inst* 1967;38:19–30.
15. Romerdahl CA, Stephens LC, Bucana C, Kripke ML. The role of ultraviolet radiation in the induction of melanocytic skin tumors in inbred mice. *Cancer Commun* 1989;1:209–16.
16. Husain Z, Pathak MA, Flotte T, Wick MM. Role of ultraviolet radiation in the induction of melanocytic tumors in hairless mice following 7,12-dimethylbenz(a)anthracene application and ultraviolet irradiation. *Cancer Res* 1991;51:4964–70.
17. de Gruijl FR, van Kranen HJ, van Schanke A. UV exposure, genetic targets in melanocytic tumors and transgenic mouse models. *Photochem Photobiol* 2005;81:52–64.
18. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility *in vivo*. *Genes Dev* 1997;11:2822–34.
19. de Vries A, Berg RJ, Wijnhoven S, et al. XPA-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of U.V.B. *Oncogene* 1998;16:2205–12.

20. Soufir N, Moles JP, Vilmer C, et al. P16 UV mutations in human skin epithelial tumors. *Oncogene* 1999;18:5477-81.
21. de Vries A, van Oostrom CT, Hofhuis FM, et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. *Nature* 1995;377:169-73.
22. Rebel H, Mosnier LO, Berg RJ, et al. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity. *Cancer Res* 2001;61:977-83.
23. Berg RJ, de Vries A, van Steeg H, de Gruijl FR. Relative susceptibilities of XPA knockout mice and their heterozygous and wild-type littermates to UVB-induced skin cancer. *Cancer Res* 1997;57:581-4.
24. Rebel H, van Steeg H, Beems RB, et al. Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice. *Cancer Res* 2002;62:1338-42.
25. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. *J Natl Cancer Inst* 1984;73:75-82.
26. van Schanke A, Jongsma MJ, Bisschop R, et al. Single UVB overexposure stimulates melanocyte proliferation in murine skin, in contrast to fractionated or UVA-1 exposure. *J Invest Dermatol* 2005;124:241-7.
27. Tronnier M, Rudolph P, Koser T, Raasch B, Brinckmann J. One single erythemagenic UV irradiation is more effective in increasing the proliferative activity of melanocytes in melanocytic naevi compared with fractionally applied high doses. *Br J Dermatol* 1997;137:534-9.
28. Ahn GY, Butt KI, Jindo T, et al. The expression of endothelin-1 and its binding sites in mouse skin increased after ultraviolet B irradiation or local injection of tumor necrosis factor α . *J Dermatol* 1998;25:78-84.
29. Kligman LH, Murphy GF. Ultraviolet B radiation increases hairless mouse mast cells in a dose-dependent manner and alters distribution of UV-induced mast cell growth factor. *Photochem Photobiol* 1996;63:123-7.
30. Hachiya A, Kobayashi A, Ohuchi A, Takema Y, Imokawa G. The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation. *J Invest Dermatol* 2001;116:578-86.
31. Powell MB, Gause PR, Hyman P, et al. Induction of melanoma in TPras transgenic mice. *Carcinogenesis* 1999;20:1747-53.
32. Dulon M, Weichenthal M, Blettner M, et al. Sun exposure and number of nevi in 5- to 6-year-old European children. *J Clin Epidemiol* 2002;55:1075-81.
33. Milligan A, Gabrielli BG, Clark JM, et al. Involvement of p16^{INK4a} in cell cycle delays after low dose UV radiation. *Mutat Res* 1998;422:43-53.
34. Noonan FP, Recio JA, Takayama H, et al. Neonatal sunburn and melanoma in mice. *Nature* 2001;413:271-2.
35. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16^{INK4a} confers susceptibility to metastatic melanoma in mice. *Nature* 2001;413:83-6.
36. Mann SJ. Hair loss and cyst formation in hairless and rhino mutant mice. *Anat Rec* 1971;170:485-99.
37. Forbes PD, Davies RE. Photocarcinogenesis in hairless mice: dose response and influence of dose-delivery. In: Daynes RA, Spikes JD, editors. *Experimental and Clinical Photoimmunology*. Vol. 1. Boca Raton (Florida): CRC Press; 1983. p. 43-60.